“THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION”, Mediterr J Hematol Infect Dis, vol. 10, no. 1, p. e2018058, Oct. 2018, doi: 10.4084/mjhid.2018.058.